Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02178956 · ClinicalTrials.gov registry record · Phase 3
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 714
- Enrollment target
NCT02178956 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 714 participants.
The verdict
NCT02178956, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 714 participants
- Enrollment target
Study Summary
The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and gastroesophageal junction cancer after prior first line platinum and fluoropyrimidine based chemotherapy.
Interventions
- OTHER Placebo
- DRUG Paclitaxel
- DRUG BBI608
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 714 participants |
| Start Date | 2014-10 |
| Est. Completion | 2017-09-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02178956
The ClinicalTrials.gov registry entry for NCT02178956 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 714 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02178956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02178956 about?
NCT02178956 is a clinical study titled "A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer". The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and gastroesophageal junction cancer after prior first line platinum and fluorop...
What is the current status of trial NCT02178956?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 714 participants. The study started on 2014-10. Estimated completion is 2017-09-20.
What interventions are being tested in trial NCT02178956?
The interventions under investigation include: Placebo (OTHER), Paclitaxel (DRUG), BBI608 (DRUG).
Who is sponsoring clinical trial NCT02178956?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.